secwatch.observer — SEC 8-K summary
======================================

Issuer:     CVRx, Inc. (CVRX)
CIK:        0001235912
Form:       8-K
Filed at:   2026-05-11T20:10:52+00:00
Accession:  0001104659-26-058655
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CVRx Q1 revenue $14.8M (+20% YoY); raises FY gross margin guidance
------------------------------------------------------------------

- U.S. revenue $13.7M (+22% YoY); active implanting centers grew to 257 from 227 a year ago.
- Net loss $13.1M ($0.50 EPS) vs $13.8M ($0.53 EPS) in Q1 2025.
- First site activated and first patient enrolled in BENEFIT-HF trial; could expand indicated population ~3x.
- FY2026 guidance: revenue $63-67M; gross margin raised to 85-87% from prior 84-86%.
- Cash $72.3M; Q2 2026 revenue expected $15.1-16.1M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1235912/000110465926058655/0001104659-26-058655-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1235912/000110465926058655/tm2614163d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-058655

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer